Mentions
Extended reach
Total likes
Video views
AI synopsis
The social discussions reflect a critical stance on current drug development, exemplified by mentions of how many drugs approved by EMA and in the US show no added benefit over existing treatments. The tone underscores urgency and dissatisfaction, especially with phrases like 'no benefit' and references to complex regulatory issues, indicating active engagement with the article’s call for reform and improved patient focus.
Most discussions recognize issues in drug approval and efficacy, emphasizing that many newly approved drugs lack added benefit, which aligns with the article’s critique.
Posts show high interest, with emphasis on approval processes, efficacy, and patient needs, indicating concern for real-world impacts.
Discussions cite specific data and policies, such as statistics about approval benefits and surveillance, reflecting deep engagement.
The posts highlight significant concerns about drug safety and effectiveness, suggesting these issues could influence policy and clinical practice.
Almost 60% of all newly approved drugs have no benefit compared to standard-of-care. On the one hand, the solution to this problem is really complex (regulatory, political, economic). On the other hand, it is very simple: "focus on the needs of patients" https://t.co/0uGr3VlSp8
New drugs: where did we go wrong and what can we do better? https://t.co/eTCltQupOq
Drugs approved by EMA 2011-16 of 216 entering German market 125 did not prove added benefit over standard care.Little evidence of adequate post marketing surveillance in US only 10% of 100 reviewed showed superior efficacy! @ABPI_UK @alison_culpan https://t.co/pvrGVHeqHz
RT @andriesvdm: Almost 60% of all newly approved drugs have no benefit compared to standard-of-care. On the one hand, the solution to this…
This video provides an overview of ineffective practices in healthcare and their prevalence. It delves into psychological phenomena behind perceived treatment effectiveness and highlights research methods to discern…
Action bias in healthcare can lead to unnecessary medical interventions. This video discusses how cognitive biases influence decisions, spotlighting the significant issue of medical overuse and its implications for…
New drugs: where did we go wrong and what can we do better? https://t.co/eTCltQupOq
Drugs approved by EMA 2011-16 of 216 entering German market 125 did not prove added benefit over standard care.Little evidence of adequate post marketing surveillance in US only 10% of 100 reviewed showed superior efficacy! @ABPI_UK @alison_culpan https://t.co/pvrGVHeqHz
RT @andriesvdm: Almost 60% of all newly approved drugs have no benefit compared to standard-of-care. On the one hand, the solution to this…
RT @andriesvdm: Almost 60% of all newly approved drugs have no benefit compared to standard-of-care. On the one hand, the solution to this…
Almost 60% of all newly approved drugs have no benefit compared to standard-of-care. On the one hand, the solution to this problem is really complex (regulatory, political, economic). On the other hand, it is very simple: "focus on the needs of patients" https://t.co/0uGr3VlSp8